143 related articles for article (PubMed ID: 31009168)
1. Variability in content and dissolution profiles of MDMA tablets collected in the UK between 2001 and 2018 - A potential risk to users?
Couchman L; Frinculescu A; Sobreira C; Shine T; Ramsey J; Hecht M; Kipper K; Holt D; Johnston A
Drug Test Anal; 2019 Aug; 11(8):1172-1182. PubMed ID: 31009168
[TBL] [Abstract][Full Text] [Related]
2. Variability in the 3,4-methylenedioxymethamphetamine content of 'ecstasy' tablets in the UK.
Wood DM; Stribley V; Dargan PI; Davies S; Holt DW; Ramsey J
Emerg Med J; 2011 Sep; 28(9):764-5. PubMed ID: 20724467
[TBL] [Abstract][Full Text] [Related]
3. The content of ecstasy tablets: implications for the study of their long-term effects.
Cole JC; Bailey M; Sumnall HR; Wagstaff GF; King LA
Addiction; 2002 Dec; 97(12):1531-6. PubMed ID: 12472637
[TBL] [Abstract][Full Text] [Related]
4. The variability of ecstasy tablets composition in Brazil.
Togni LR; Lanaro R; Resende RR; Costa JL
J Forensic Sci; 2015 Jan; 60(1):147-51. PubMed ID: 25125149
[TBL] [Abstract][Full Text] [Related]
5. Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users.
Brunt TM; Koeter MW; Niesink RJ; van den Brink W
Psychopharmacology (Berl); 2012 Apr; 220(4):751-62. PubMed ID: 21993879
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological content of tablets sold as "ecstasy": results from an online testing service.
Tanner-Smith EE
Drug Alcohol Depend; 2006 Jul; 83(3):247-54. PubMed ID: 16364567
[TBL] [Abstract][Full Text] [Related]
7. Chemical profiling of 3,4-methylenedioxymethamphetamine (MDMA) tablets seized in Hong Kong.
Cheng WC; Poon NL; Chan MF
J Forensic Sci; 2003 Nov; 48(6):1249-59. PubMed ID: 14640267
[TBL] [Abstract][Full Text] [Related]
8. 3,4-Methylenedioxymethamphetamine quantification via benchtop
Frinculescu A; Maier AFG; Shine T; Ramsey J; Araneda JF; Riegel SD; Frascione N; Abbate V
J Pharm Biomed Anal; 2022 May; 214():114728. PubMed ID: 35349940
[TBL] [Abstract][Full Text] [Related]
9. Content of ecstasy in the Netherlands: 1993-2008.
Vogels N; Brunt TM; Rigter S; van Dijk P; Vervaeke H; Niesink RJ
Addiction; 2009 Dec; 104(12):2057-66. PubMed ID: 19804461
[TBL] [Abstract][Full Text] [Related]
10. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity.
Parrott AC
Psychopharmacology (Berl); 2004 May; 173(3-4):234-41. PubMed ID: 15007594
[TBL] [Abstract][Full Text] [Related]
11. Organic impurity profiling of 3,4-methylenedioxymethamphetamine (MDMA) tablets seized in The Netherlands.
van Deursen MM; Lock ER; Poortman-van der Meere AJ
Sci Justice; 2006; 46(3):135-52. PubMed ID: 17388242
[TBL] [Abstract][Full Text] [Related]
12. [Ecstasy--the status in French-speaking Switzerland. Composition of seized drugs, analysis of biological specimens and short review of its pharmacological action and toxicity].
Giroud C; Augsburger M; Sadeghipour F; Varesio E; Veuthey JL; Rivier L
Praxis (Bern 1994); 1997 Mar; 86(13):510-23. PubMed ID: 9157497
[TBL] [Abstract][Full Text] [Related]
13. Use of MDA (the "love drug") and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA).
Kalasinsky KS; Hugel J; Kish SJ
J Forensic Sci; 2004 Sep; 49(5):1106-12. PubMed ID: 15461119
[TBL] [Abstract][Full Text] [Related]
14. Impact of a transient instability of the ecstasy market on health concerns and drug use patterns in The Netherlands.
Brunt TM; Niesink RJ; van den Brink W
Int J Drug Policy; 2012 Mar; 23(2):134-40. PubMed ID: 21741814
[TBL] [Abstract][Full Text] [Related]
15. Supported liquid-liquid extraction of the active ingredient (3,4-methylenedioxymethylamphetamine) from ecstasy tablets for isotopic analysis.
de Korompay A; Hill JC; Carter JF; NicDaeid N; Sleeman R
J Chromatogr A; 2008 Jan; 1178(1-2):1-8. PubMed ID: 18070626
[TBL] [Abstract][Full Text] [Related]
16. Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users.
Morefield KM; Keane M; Felgate P; White JM; Irvine RJ
Addiction; 2011 Jul; 106(7):1293-300. PubMed ID: 21320226
[TBL] [Abstract][Full Text] [Related]
17. mCPP: an undesired addition to the ecstasy market.
Bossong MG; Brunt TM; Van Dijk JP; Rigter SM; Hoek J; Goldschmidt HM; Niesink RJ
J Psychopharmacol; 2010 Sep; 24(9):1395-401. PubMed ID: 19304863
[TBL] [Abstract][Full Text] [Related]
18. Analysis of ecstasy tablets using capillary electrophoresis with capacitively coupled contactless conductivity detection.
Porto SK; Nogueira T; Blanes L; Doble P; Sabino BD; do Lago CL; Angnes L
J Forensic Sci; 2014 Nov; 59(6):1622-6. PubMed ID: 25039689
[TBL] [Abstract][Full Text] [Related]
19. A contribution to the chemical profiling of 3,4-methylenedioxymethamphetamine (MDMA) tablets.
Gimeno P; Besacier F; Chaudron-Thozet H; Girard J; Lamotte A
Forensic Sci Int; 2002 Jun; 127(1-2):1-44. PubMed ID: 12098525
[TBL] [Abstract][Full Text] [Related]
20. Combining attenuated total reflectance- infrared spectroscopy and chemometrics for the identification and the dosage estimation of MDMA tablets.
Deconinck E; Van Campenhout R; Aouadi C; Canfyn M; Bothy JL; Gremeaux L; Blanckaert P; Courselle P
Talanta; 2019 Apr; 195():142-151. PubMed ID: 30625524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
